Wykeisha Highsmith
Psychiatric/Mental Health · Enfield, CTNPI 1386791051
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 83 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 9.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $878, 4.0 times the $220 reported in 2023.
Across 83 payments — averaging $21.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corium, LLC$165
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$162
- Tris Pharma Inc$132
- Teva Pharmaceuticals USA, Inc.$126
- Alkermes, Inc.$118
- Otsuka America Pharmaceutical, Inc.$112
- plus $940 from 17 others
What the payments were for
- Food & beverage$1,70897%
- Education$493%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corium, LLC | 8 | $165 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $162 |
| Tris Pharma Inc | 6 | $132 |
| Teva Pharmaceuticals USA, Inc. | 7 | $126 |
| Alkermes, Inc. | 6 | $118 |
| Otsuka America Pharmaceutical, Inc. | 5 | $112 |
| Lundbeck LLC | 4 | $104 |
| Neurocrine Biosciences, Inc. | 4 | $98 |
| Neos Therapeutics, LP | 4 | $93 |
| AbbVie | 5 | $89 |
| Johnson & Johnson | 3 | $80 |
| Ironshore Pharmaceuticals Inc. | 3 | $66 |
| Axsome Therapeutics, Inc. | 3 | $63 |
| Collegium Pharmaceutical, Inc. | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Bausch Health US, LLC | 2 | $41 |
| Idorsia Pharmaceuticals US Inc | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 2 | $33 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $29 |
| Noven Therapeutics, LLC | 1 | $20 |
| Boston Scientific | 1 | $20 |
| OWP Pharmaceuticals, Inc. | 1 | $19 |
How this compares
$1,757 in reported general payments places this provider in the 80th percentile of 679 psychiatric/mental health providers in Connecticut.
See all psychiatric/mental health providers in Connecticut →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Propranolol Hcl ErPropranolol Hcl | 25 | $173 |
| Quetiapine Fumarate | 28 | $80 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Enfield
- Cristina MeehanNew Britain$224K
- Samantha MrazBridgeport$87K
- Philip FrickManchester$31K
- Gia SantoroWest Haven$25K
- Donna DraperDanbury$19K
- Zahida SairitupaDanbury$19K
- Hui HuNorwich$19K
- Patrick GagnonMilford$15K
- Max Greger-MoserNew Haven$15K
- Richard ComshawRocky Hill$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.